All In Biotech

Drug Trial Radar · NCT03974178

Fexinidazole in Human African Trypanosomiasis Due to T. b. Rhodesiense

Efficacy and Safety of Fexinidazole in Patients With Human African Trypanosomiasis (HAT) Due to Trypanosoma Brucei Rhodesiense: a Multicentre, Open-label Clinical Trial

Last checked: Nov 20, 2026Latest source record: Jan 30, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

45

Actual

Start

Sep 29, 2019

Primary completion

Nov 30, 2021

Study completion Oct 12, 2022

Sponsor

Lead sponsor
Drugs for Neglected DiseasesAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
European and Developing Countries Clinical Trials Partnership (EDCTP)
First posted
Jun 4, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 6 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The ultimate goal of this study is to show that fexinidazole offers an alternative over the existing treatments of Human African trypanosomiasis due to Trypanosoma brucei rhodesiense (r-HAT): melarsoprol in patients with stage 2 r-HAT and suramin in patients with stage 1 r-HAT. The main questions it aims to answer are: * Is the short-term fatality rate and failure rate associated with fexinidazole lower than those of melarsoprol in patients with stage 2 r-HAT? * Is the long-term failure rate associated with fexinidazole lower than that of melarsoprol in patients with stage 2 r-HAT? * Can fexinidazole in patients with stage 1 r-HAT replace the treatment with suramin? * Is fexinidazole treatment safe in patient with r-HAT, regardless of stage? Participants will receive fexinidazole oral treatment for 10 days. Regular blood draws and lumbar punctures will be performed over 12 months to confirm the cure of the disease. Other assessments will include the recording of adverse events, signs and symptoms of the disease, laboratory tests, vital signs, electrocardiograms.

Conditions

  • Trypanosomiasis, African
  • Sleeping Sickness
  • Trypanosoma Brucei Rhodesiense; Infection

Interventions

  • FexinidazoleDrug

    Tablets of 600 mg; Participants with a weight between 20 and 34 kg received 1200 mg (2 tablets) for 4 days, then 600 mg (1 tablet) for 6 days (with food); Participants with a weight of 35 kg and above received 1800 mg (3 tablets) for 4 days, then 1200 mg (2 tablets) for 6 days (with food)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Evaluable Patients With Stage 2 r-HAT Who Died by the End of Hospitalization, Considering Only Deaths Possibly Related to r-HAT or FexinidazoleTime frame: 12 to 18 days after start of treatment

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Rumphi District Hospital

    Rumphi, Malawi

  • Lwala Hospital

    Lwala, Kadeberamaido, Uganda

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.